Henderson Neil C, Pollock Katharine J, Frew John, Mackinnon Alison C, Flavell Richard A, Davis Roger J, Sethi Tariq, Simpson Kenneth J
Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4TJ, UK.
Gut. 2007 Jul;56(7):982-90. doi: 10.1136/gut.2006.104372. Epub 2006 Dec 21.
Acute hepatic failure secondary to paracetamol poisoning is associated with high mortality. C-jun (NH2) terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and is a key intracellular signalling molecule involved in controlling the fate of cells.
To examine the role of JNK in paracetamol-induced acute liver failure (ALF).
A previously developed mouse model of paracetamol poisoning was used to examine the role of JNK in paracetamol-induced ALF.
Paracetamol-induced hepatic JNK activation both in human and murine paracetamol hepatotoxicity and in our murine model preceded the onset of hepatocyte death. JNK inhibition in vivo (using two JNK inhibitors with different mechanisms of action) markedly reduced mortality in murine paracetamol hepatotoxicity, with a significant reduction in hepatic necrosis and apoptosis. In addition, delayed administration of the JNK inhibitor was more effective than N-acetylcysteine after paracetamol poisoning in mice. JNK inhibition was not protective in acute carbon tetrachloride-mediated or anti-Fas antibody-mediated hepatic injury, suggesting specificity for the role of JNK in paracetamol hepatotoxicity. Furthermore, disruption of the JNK1 or JNK2 genes did not protect against paracetamol-induced hepatic damage. Pharmacological JNK inhibition had no effect on paracetamol metabolism, but markedly inhibited hepatic tumour necrosis foctor alpha (TNF alpha) production after paracetamol poisoning.
These data demonstrated a central role for JNK in the pathogenesis of paracetamol-induced liver failure, thereby identifying JNK as an important therapeutic target in the treatment of paracetamol hepatotoxicity.
对乙酰氨基酚中毒继发的急性肝衰竭与高死亡率相关。C-Jun氨基末端激酶(JNK)是丝裂原活化蛋白激酶家族的成员,是参与控制细胞命运的关键细胞内信号分子。
研究JNK在对乙酰氨基酚诱导的急性肝衰竭(ALF)中的作用。
使用先前建立的对乙酰氨基酚中毒小鼠模型来研究JNK在对乙酰氨基酚诱导的ALF中的作用。
在人和小鼠对乙酰氨基酚肝毒性中以及在我们的小鼠模型中,对乙酰氨基酚诱导的肝脏JNK激活先于肝细胞死亡的发生。体内JNK抑制(使用两种作用机制不同的JNK抑制剂)显著降低了小鼠对乙酰氨基酚肝毒性的死亡率,肝坏死和凋亡明显减少。此外,在小鼠对乙酰氨基酚中毒后,延迟给予JNK抑制剂比N-乙酰半胱氨酸更有效。JNK抑制在急性四氯化碳介导的或抗Fas抗体介导的肝损伤中没有保护作用,表明JNK在对乙酰氨基酚肝毒性中的作用具有特异性。此外,JNK1或JNK2基因的破坏并不能防止对乙酰氨基酚诱导的肝损伤。药理学上的JNK抑制对对乙酰氨基酚代谢没有影响,但在对乙酰氨基酚中毒后显著抑制肝肿瘤坏死因子α(TNFα)的产生。
这些数据证明JNK在对乙酰氨基酚诱导的肝衰竭发病机制中起核心作用,从而确定JNK是治疗对乙酰氨基酚肝毒性的重要治疗靶点。